Today: 1 May 2026
Warby Parker stock price today: WRBY falls nearly 4% in thin year-end trading
30 December 2025
1 min read

Warby Parker stock price today: WRBY falls nearly 4% in thin year-end trading

NEW YORK, December 30, 2025, 13:34 ET — Regular session

  • Warby Parker shares slid in early afternoon trade, lagging the broader market.
  • Thin year-end trading set a choppy tone across U.S. equities.
  • Investors awaited U.S. Federal Reserve meeting minutes later Tuesday.

Warby Parker Inc (WRBY) shares fell about 3.9% to $22.11 in early afternoon trading on Tuesday, after ending Monday at $23.00. The stock opened at $22.90 and traded between $21.87 and $23.13, with nearly 3 million shares changing hands; the company is valued at about $3.4 billion.

The slide comes with just a handful of sessions left in 2025, a stretch when trading often thins out and price moves can look outsized. Thin trading means fewer buyers and sellers, so routine position changes can move a stock more than usual.

U.S. stocks were little changed in choppy trade, and investors were waiting for minutes from the Federal Reserve’s December meeting later Tuesday. “It’s just a healthy rebalancing of allocations more so than an emotionally driven sell-off,” said Mark Hackett, chief market strategist at Nationwide. Reuters

Retail shares were mixed, with the SPDR S&P Retail ETF down about 0.3%. National Vision Holdings, another eyewear retailer, fell about 1.7%.

Warby Parker sells prescription and non-prescription eyewear, including glasses and contact lenses, and provides optical services through its stores and e-commerce platform.

The stock drew investor attention this month after Warby Parker said it is collaborating with Alphabet’s Google to develop lightweight AI-powered glasses, with the first product expected to launch in 2026.

That initiative gives the consumer brand a new technology angle, but investors have still been weighing execution risk and near-term fundamentals. In a low-volume week, traders tend to cut exposure quickly when the tape turns one-way.

Rates remain part of the story for consumer-facing growth stocks. Lower interest rates can lift valuations by making future profits more valuable in today’s dollars, while higher yields can do the opposite.

For Warby Parker, traders will be watching how demand holds up through the holiday quarter, along with any signals on pricing and promotions. Those details can shape expectations for margins as the company continues to invest in growth.

The next major company catalyst is likely to be its next earnings report and outlook for 2026, expected early next year. Investors typically focus on revenue growth, customer trends and cost control in those updates.

Investors will also look for clearer signals on what the Google collaboration means for distribution and timing, areas the companies have not detailed publicly. Any new milestones or commercial terms could reset expectations again.

Stock Market Today

  • Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK
    May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines and capital strategies amid challenging market conditions.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 01.05.2026

1 May 2026
LIVEMarkets rolling coverageStarted: May 1, 2026, 12:00 AM EDTUpdated: May 1, 2026, 12:17 AM EDT Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines
Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026
Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.
Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026
Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.
Edgewise Therapeutics stock steady midday after $3 million insider sale filing — what’s next for EWTX
Previous Story

Edgewise Therapeutics stock steady midday after $3 million insider sale filing — what’s next for EWTX

Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus
Next Story

Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

Go toTop